glp-1 cardiovascular outcomes trial results august 2025 of trials comparing receptor Semaglutide Shows Secondary Cardiovascular Prevention

These are all talking about a similar concept: using lower-than-usual amounts of GLP-1based drugs and increasing more slowly than standard protocols, under medical supervision

New Cell

The long-term benefits of weight loss on urinary health are substantial and lasting

Any decision about pharmacological weight management in this population should be made collaboratively between the patient, their GP, and ideally a renal specialist

The existing urinary dilation code for nephrostomy tract creation (50395) has been deleted and replaced with two new codes that are differentiated by whether a new access is required

The duration of treatment with Semaglutide / Cyanocobalamin Injection varies considerably based on individual circumstances, treatment goals, and ongoing response to therapy